Role of Autophagy and Evaluation the Effects of MicroRNAs 214, 132, 34c and Prorenin Receptor in a Rat Model of Focal Segmental Glomerulosclerosis
Overview
Biology
Physiology
Authors
Affiliations
Aims: Focal segmental glomerulosclerosis (FSGS) is the common cause of chronic renal disease worldwide. Although there are many etiologic factors which have common theme of podocyte injury conclusive etiology is not clearly understood. In this study, we aimed to explore the role of autophagy in the pathogenesis of podocyte injury, which is the key point in disease progression, and the roles of intrarenal microRNAs and the prorenin receptor (PRR) in the 5/6 nephrectomy and adriamycin nephropathy models of FSGS.
Main Methods: For experimental FSGS model, 5/6 nephrectomy and adriamycin nephropathy models were created and characterized in adult Sprague Dawley rats. Microarray analysis was performed on FSGS and control groups that was confirmed by q-RT-PCR. Beclin1, LC3B, PRR, ATG7 and ATG5 expression were evaluated by western blotting and immunohistochemistry. Also, Beclin1 and PRR expression were measured by ELISA. Glomerular podocyte isolation was performed and autophagic activity was evaluated in podocytes before and after transfection with miRNA mimic and antagonists.
Key Findings: Glomerular expression of Beclin1, LC3B, PRR, ATG7 and ATG5 were significantly lower in the 5/6 nephrectomy than adriamycin nephropathy group and in both groups lower when compared to control groups. Western blot results were consistent with immunohistochemical data. Electron microscopy revealed signs of impaired autophagy in FSGS. Autophagic activity decreased significantly after miR-214, miR-132 and miR-34c mimics and increased after transfection with antagonists.
Significance: These results showed that the role of autophagic activity and decreased expression of PRR in FSGS pathogenesis and miR-34c, miR-132 and miR-214 could be a potential treatment strategy by regulating autophagy.
Calycosin prevents NLRP3-induced gut fibrosis by regulating IL-33/ST2 axis.
Liao X, Xie H, Yu S Heliyon. 2024; 10(9):e30240.
PMID: 38726105 PMC: 11078877. DOI: 10.1016/j.heliyon.2024.e30240.
Podocyte-targeted therapies - progress and future directions.
Meliambro K, He J, Campbell K Nat Rev Nephrol. 2024; 20(10):643-658.
PMID: 38724717 DOI: 10.1038/s41581-024-00843-z.
Precision medicine for focal segmental glomerulosclerosis.
Xie Y, Liu F Kidney Res Clin Pract. 2024; 43(6):709-723.
PMID: 38325863 PMC: 11615440. DOI: 10.23876/j.krcp.23.227.
Li Y, Fan J, Zhu W, Niu Y, Wu M, Zhang A Kidney Dis (Basel). 2023; 9(4):254-264.
PMID: 37900001 PMC: 10601935. DOI: 10.1159/000530344.
Ouyang Z, Shao L, Wang W, Ke T, Chen D, Zheng G Redox Rep. 2023; 28(1):2251237.
PMID: 37652897 PMC: 10472869. DOI: 10.1080/13510002.2023.2251237.